Medical devices are one of the most important subdivisions in the life and health industry. As the COVID-19 epidemic spreads around the world, the market demand for medical equipment, medical imaging, medical protective equipment and other medical devices in various countries has surged.

In the first quarter of 2020, domestic medical device leader Mindray Medical's revenue was close to 4.8 billion yuan, and Yuyue Medical's revenue was close to 1.4 billion yuan.

The revenue of six companies including BGI, Yingke Medical, Shandong Pharmaceutical Glass, Ogilvy Medical, Wondfo Biologics, and Mike Biotech all exceeded 500 million yuan.

Yuyue Medical, Lepu Medical, Da'an Gene, Jianfan Biotech, Meikang Biotech, Lanfan Medical, BGI, Yingke Medical, Shuoshi Biotech, etc. all had profits exceeding 100 million in the first quarter.

Compared with the first quarter of 2019, the profits of Yingke Medical, Meikang Biotech, and Da'an Gene increased by 284%, 140%, and 607% respectively, reaching 130 million yuan, 170 million yuan, and 200 million yuan.

The sudden epidemic is a "big test" for medical device companies, and it is also an accelerator for the development of China's medical device industry.

At the same time, as my country's medical device policy environment continues to improve in recent years, a number of major policies such as deepening review and approval, high-value consumable management, DRG, SPD, medical consortium, hierarchical diagnosis and treatment, and medical device registrant systems have been intensively introduced, and market demand has Increasingly prosperous, the medical device industry has officially entered a golden development period.

AI, robots and other smart medical technologies.

As a hot topic in the industry in the past two years, smart devices such as AI imaging, AI electrocardiographs, and AI medical robots have performed prominently in epidemic control.

Multi-dimensional methods such as massive data processing, disease marker screening, treatment plan simulation, and unmanned care have comprehensively improved the efficiency and accuracy of diagnosis of the new coronavirus epidemic.

In the long run, high technologies represented by AI, robots, 5G, big data, genetic technology, VR, and cloud medical care will be deeply applied to many fields such as medical diagnosis, treatment, and disease prevention beyond expectations.

IVD field.

After the outbreak, more than 100 companies, including Wondfo Bio, Antu Bio, Da'an Gene, New Industries, Mike, Meikang Bio, Jidan Bio, Kanghua Bio, and Youlite, etc., have successively launched test kits and various

Rapid detection methods effectively solve the problem of epidemic detection.

Among them, POCT products have made great contributions in epidemic prevention and control due to their portability and rapidity.

It is foreseeable that in the future, the demand for POCT testing products, small biochemistry instruments, hemocytometers, small closed automated PCR equipment, microfluidic equipment, and gene sequencing equipment that are convenient, miniaturized, and suitable for rapid diagnosis will become increasingly prominent, or they may become the next

Breaking point.

Third-party medical laboratories.

On February 4, Premier Li Keqiang pointed out at the work conference on responding to the new coronavirus infection pneumonia epidemic that qualified third-party testing institutions are allowed to carry out nucleic acid testing.

In the future, as medical institutions continue to open up, the exponential growth of third-party laboratories including testing, pathology, imaging, hemodialysis, etc. will be greatly promoted.

Imaging and monitoring diagnostic equipment.

Such as CT, DR, monitors, oximeters, etc., will also be catalyzed by this epidemic and benefit from the sinking of medical resources at the grassroots level, the construction of fever clinics, critical ICU wards, and separate isolation hospitals, ushering in a new round of

Growth opportunities.

Disinfection infection control and health protection products.

Products related to the epidemic this time, including disinfection and infection control, masks, thermometers, gloves, and anti-viral supplies, are in short supply.

The demand for home diagnostic and monitoring medical equipment and wearable medical equipment such as blood pressure monitors, blood glucose meters, oximeters, electronic stethoscopes, and smart bracelets has skyrocketed.

It is foreseeable that after this epidemic, people will pay more and more attention to health, and various types of preventive care, medical and physical integration household products, and health and science education software will have a large market in the future.

Market demand has surged, and domestic substitution of imports has accelerated.

In recent years, with the development of Chinese IVD companies, the stability of instruments, accuracy of test results, and academic promotion and service capabilities have been greatly improved. It can be said that in biochemistry, chemiluminescence, blood cells, molecular diagnosis, and rapid testing,

There are products on other technology platforms that are comparable to imported first-tier brands, which means that the era of foreign companies relying on their brands to obtain high profits will soon pass.

Substituting imported products with domestic products will undoubtedly accelerate after the epidemic.

The impact of the "black swan" brought by the epidemic on the country's economy, society, and culture continues.

Catalyzed by the acceleration of the epidemic, the medical device industry, as one of the important indicators to measure a country's scientific and technological progress and the modernization development level of the national economy, has promising future prospects.

Xi'an Sanyuan Park Operation Management Co., Ltd. is a professional third-party park operating organization in China, focusing on urban industry research and planning, park investment planning and implementation, and third-party park operation and management.